From: Is lobe specific lymph node dissection adequate for cN0–1 non-small cell lung cancer?
Variables | NLSLNM (n = 129) | LSLNM (n = 230) | P value |
---|---|---|---|
Sex | 0.149 | ||
Male | 61 (47.3%) | 127 (55.2%) | |
Female | 68 (52.7%) | 103 (44.8%) | |
Age, years | 0.176 | ||
Median (range) | 61 (26–83) | 60.5 (27–80) | |
Smoking history | 42 (32.6%) | 115 (50.0%) | 0.001 |
Hypertension | 21 (16.3%) | 66 (28.7%) | 0.008 |
Diabetes | 8 (6.2%) | 14 (6.1%) | 0.965 |
Other pulmonary diseases | 5 (3.9%) | 5 (2.2%) | 0.544 |
Other malignant tumors within 5 years | 0 (0) | 4 (1.7%) | 0.326 |
CEA level | 0.004 | ||
>5 ng/ml | 65 (50.4%) | 80 (34.8%) | |
≤5 ng/ml | 64 (49.6%) | 150 (65.2%) | |
Tumor location | < 0.001 | ||
RUL | 19 (14.7%) | 59 (25.7%) | |
RLL | 54 (41.9%) | 46 (20.0%) | |
LUL | 26 (20.2%) | 71 (30.9%) | |
LLL | 30 (23.3%) | 54 (23.5%) | |
CT characteristics | 0.404 | ||
GGO | 1 (0.8%) | 1 (0.4%) | |
Partially solid | 4 (3.1%) | 14 (6.1%) | |
Solid | 124 (96.1%) | 215 (93.5%) | |
Clinical T stage | 0.493 | ||
T1a | 2 (1.6%) | 4 (1.7%) | |
T1b | 19 (14.7%) | 49 (21.3%) | |
T1c | 47 (36.4%) | 70 (30.4%) | |
T2a | 27 (20.9%) | 56 (24.3%) | |
T2b | 20 (15.5%) | 27 (11.7%) | |
T3 | 13 (10.1%) | 19 (8.3%) | |
T4 | 1 (0.8%) | 5 (2.2%) | |
Clinical N stage | 0.647 | ||
N0 | 118 (91.5%) | 207 (90.0%) | |
N1 | 11 (8.5%) | 23 (10.0%) | |
Surgical approach | 0.052 | ||
Thoracotomy | 71 (55.0%) | 102 (44.3%) | |
VATS | 58 (45.0%) | 128 (55.7%) | |
Surgical resection | 0.345 | ||
Segmentectomy | 2 (1.6%) | 6 (2.6%) | |
Lobectomy | 120 (93.0%) | 207 (90.0%) | |
Sleeve lobectomy | 2 (1.6%) | 11 (4.8%) | |
Pneumonectomy | 5 (3.9%) | 6 (2.6%) |